WO2012169822A3 - 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 - Google Patents

암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 Download PDF

Info

Publication number
WO2012169822A3
WO2012169822A3 PCT/KR2012/004531 KR2012004531W WO2012169822A3 WO 2012169822 A3 WO2012169822 A3 WO 2012169822A3 KR 2012004531 W KR2012004531 W KR 2012004531W WO 2012169822 A3 WO2012169822 A3 WO 2012169822A3
Authority
WO
WIPO (PCT)
Prior art keywords
suppressing
vasculogenesis
fusion protein
cell growth
same
Prior art date
Application number
PCT/KR2012/004531
Other languages
English (en)
French (fr)
Other versions
WO2012169822A9 (ko
WO2012169822A2 (ko
Inventor
홍효정
씽로히트
Original Assignee
강원대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020120061054A external-priority patent/KR101397088B1/ko
Application filed by 강원대학교산학협력단 filed Critical 강원대학교산학협력단
Priority to US14/125,021 priority Critical patent/US9605043B2/en
Publication of WO2012169822A2 publication Critical patent/WO2012169822A2/ko
Publication of WO2012169822A9 publication Critical patent/WO2012169822A9/ko
Publication of WO2012169822A3 publication Critical patent/WO2012169822A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

본 발명은 암 특이적 항체와 혈관신생 억제제가 결합된 융합 단백질 및 이를 포함하는 암 치료용 조성물에 관한 것으로, 구체적으로, 본 발명에 따른 바람직한 암 특이적 항체는 트라스투주맵 또는 이의 단편이며, 혈관신생 억제제는 VEGF-트랩이다. 본 발명에 따른 융합 단백질을 이용하면 트라스투주맵이나 VEGF-트랩에 비해낮은 용량으로도 효율적으로 혈관신생 및 암 세포의 증식을 억제할 수 있으며, 부작용도 최소화될 수 있다는 장점이 있다.
PCT/KR2012/004531 2011-06-10 2012-06-08 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물 WO2012169822A2 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/125,021 US9605043B2 (en) 2011-06-10 2012-06-08 Fusion protein for suppressing cancer cell growth and suppressing vasculogenesis, and anticancer composition comprising same

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2011-0056089 2011-06-10
KR20110056089 2011-06-10
KR1020120061054A KR101397088B1 (ko) 2011-06-10 2012-06-07 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
KR10-2012-0061054 2012-06-07

Publications (3)

Publication Number Publication Date
WO2012169822A2 WO2012169822A2 (ko) 2012-12-13
WO2012169822A9 WO2012169822A9 (ko) 2013-02-07
WO2012169822A3 true WO2012169822A3 (ko) 2013-03-28

Family

ID=47296618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004531 WO2012169822A2 (ko) 2011-06-10 2012-06-08 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물

Country Status (1)

Country Link
WO (1) WO2012169822A2 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863224A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP2938634A2 (en) * 2012-12-28 2015-11-04 AbbVie Inc. Dual specific binding proteins having a receptor sequence
US9644021B2 (en) 2013-01-11 2017-05-09 The California Institute For Biomedical Research Bovine fusion antibodies
EP3152238A4 (en) * 2014-06-06 2018-01-03 The California Institute for Biomedical Research Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof
US11161891B2 (en) 2015-12-09 2021-11-02 The Scripps Research Institute Relaxin immunoglobulin fusion proteins and methods of use
CR20200282A (es) * 2017-11-27 2021-02-18 4D Molecular Therapeutics Inc Cápsides variantes de virus adenoasociados y su uso para inhibir la angiogénesis
CN107904251B (zh) * 2017-12-28 2020-06-02 吉林大学 TAT-hEGF融合蛋白的制备及其在隐形面膜的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050045727A (ko) * 2003-11-12 2005-05-17 학교법인 인제학원 암세포 표적성 유전자 전달방법
KR20070034512A (ko) * 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
KR20080096598A (ko) * 2006-03-22 2008-10-30 에프. 호프만-라 로슈 아게 혈관 내피 성장 인자에 대한 항체 및 인간 상피 성장 인자 수용체 유형 2 에 대한 항체를 이용한 종양 치료
KR20090031897A (ko) * 2006-06-12 2009-03-30 리셉터 바이오로직스 인크 전-세포 표면 수용체-특이적 치료제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050045727A (ko) * 2003-11-12 2005-05-17 학교법인 인제학원 암세포 표적성 유전자 전달방법
KR20070034512A (ko) * 2004-06-18 2007-03-28 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
KR20080096598A (ko) * 2006-03-22 2008-10-30 에프. 호프만-라 로슈 아게 혈관 내피 성장 인자에 대한 항체 및 인간 상피 성장 인자 수용체 유형 2 에 대한 항체를 이용한 종양 치료
KR20090031897A (ko) * 2006-06-12 2009-03-30 리셉터 바이오로직스 인크 전-세포 표면 수용체-특이적 치료제

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XIAO-FENG LE ET AL.: "Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2", CELL CYCLE, vol. 7, no. ISSUE, December 2008 (2008-12-01), pages 3747 - 3758 *

Also Published As

Publication number Publication date
WO2012169822A9 (ko) 2013-02-07
WO2012169822A2 (ko) 2012-12-13

Similar Documents

Publication Publication Date Title
WO2012169822A3 (ko) 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
MX358224B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado.
WO2013006490A3 (en) Antibodies that specifically bind to tim3
WO2012058588A3 (en) Novel egfr-binding molecules and immunoconjugates thereof
NZ711946A (en) Newcastle disease viruses and uses thereof
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
WO2012019024A3 (en) Her3-binding molecules and immunoconjugates thereof
MX2020009223A (es) Anticuerpos anti-fgfr2iiib afucosilados.
WO2014004427A8 (en) Anti-egfr antibodies and uses thereof
MX347164B (es) Anticuerpos anti-il-36r.
MY173839A (en) Cd37-binding molecules and immunoconjugates thereof
NZ606195A (en) Methods and compositions for liver cancer therapy
WO2014089169A3 (en) Immunotherapy with binding agents
MX2014012978A (es) Regiones de anticuerpo modificado y sus usos.
UA113388C2 (xx) ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ с-МЕТ
MX357965B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar.
WO2013048883A3 (en) Anti-erbb3 antibodies and uses thereof
AU2012335543A8 (en) HER3 antibodies and uses thereof
WO2013021279A3 (en) Highly galactosylated antibodies
WO2011146879A3 (en) Methods and compositions related to modulating autophagy
PH12014502628A1 (en) Compositions and methods related to the prevention and treatment of rabies infection
WO2011083090A3 (en) Methods for treating breast cancer
WO2011056021A3 (ko) 벤조헤테로사이클 유도체의 암 예방 및 치료 또는 암 전이 억제를 위한 용도
EP4282881A3 (en) Antibodies against csf-1r
WO2012003470A3 (en) Antibody formulations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12797094

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 14125021

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12797094

Country of ref document: EP

Kind code of ref document: A2